NCT03854903 2025-02-06
WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor
Georgetown University
Phase 1 Completed
Clinical Trials
4 trialsNCT00319254 2013-01-31
Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer
Pfizer
Phase 2 Completed
NCT00759837 2009-07-16
Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 1 Completed
NCT00777530 2008-10-23
Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 1 Completed